We provide you with 20 years of free, institutional-grade data for REPL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of REPL. Explore the full financial landscape of REPL stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Hill Emily Luisa | Grant, award...etc | 26,665 | 2024-04-03 | ||
| Sarchi Christopher | Grant, award...etc | 22,225 | 2024-04-03 | ||
| Schwendenman Andrew | Grant, award...etc | 17,775 | 2024-04-03 | ||
| Patel Sushil | Grant, award...etc | 83,335 | 2024-04-03 | ||
| Xynos Konstantinos | Grant, award...etc | 26,665 | 2024-04-03 | ||
| Xynos Konstantinos | Sale | -7,313 | $10.92 | $79,858 | 2023-11-17 |
| Sarchi Christopher | Sale | -5,255 | $10.92 | $57,385 | 2023-11-17 |
| Hill Emily Luisa | Grant, award...etc | 83,330 | 2023-09-20 | ||
| Esposito Pamela | Sale | -5,658 | $20.01 | $113,217 | 2023-09-13 |
| Esposito Pamela | Derivatives Exercise | 5,658 | 2023-09-13 | ||
| Esposito Pamela | Sale | -18,600 | $20.01 | $372,186 | 2023-08-24 |
| Esposito Pamela | Derivatives Exercise | 18,600 | 2023-08-24 | ||
| Esposito Pamela | Sale | -1,400 | $20 | $28,000 | 2023-08-15 |
| Esposito Pamela | Derivatives Exercise | 1,400 | 2023-08-15 | ||
| Sarchi Christopher | Initial | 2023-07-26 | |||
| Esposito Pamela | Sale | -20,000 | $21.63 | $432,600 | 2023-07-11 |
| Esposito Pamela | Derivatives Exercise | 20,000 | 2023-07-11 | ||
| Lewis Tanya | Sale | -12,860 | $24.1 | $309,926 | 2023-06-15 |
| Patel Sushil | Sale | -5,698 | $24.11 | $137,379 | 2023-06-15 |
| Schwendenman Andrew | Initial | 2023-05-18 | |||
| Patel Sushil | Sale | -15,575 | $18.05 | $281,129 | 2023-05-18 |
| Lewis Tanya | Sale | -12,207 | $18.05 | $220,336 | 2023-05-18 |
| Coffin Robert | Sale | -7,861 | $18.05 | $141,891 | 2023-05-18 |
| Love Colin | Sale | -10,775 | $18.05 | $194,489 | 2023-05-18 |
| Franchi Jean M. | Sale | -11,351 | $18.05 | $204,886 | 2023-05-18 |
| Esposito Pamela | Sale | -5,966 | $18.05 | $107,686 | 2023-05-18 |
| Astley-Sparke Philip | Sale | -17,902 | $18.05 | $323,131 | 2023-05-18 |
| Xynos Konstantinos | Sale | -771 | $18.05 | $13,917 | 2023-05-18 |
| Esposito Pamela | Grant, award...etc | 40,000 | 2023-04-04 | ||
| Xynos Konstantinos | Grant, award...etc | 50,000 | 2023-04-04 | ||
| Franchi Jean M. | Grant, award...etc | 45,000 | 2023-04-04 | ||
| Love Colin | Grant, award...etc | 40,000 | 2023-04-04 | ||
| Lewis Tanya | Grant, award...etc | 40,000 | 2023-04-04 | ||
| Patel Sushil | Grant, award...etc | 40,000 | 2023-04-04 | ||
| Coffin Robert | Grant, award...etc | 45,000 | 2023-04-04 | ||
| Astley-Sparke Philip | Grant, award...etc | 142,100 | 2023-04-04 | ||
| Esposito Pamela | Sale | -15,000 | $25.03 | $375,450 | 2022-12-13 |
| Esposito Pamela | Derivatives Exercise | 15,000 | 2022-12-13 | ||
| Xynos Konstantinos | Initial | 2022-12-05 | |||
| Xynos Konstantinos | Grant, award...etc | 17,500 | 2022-12-05 | ||
| Love Colin | Sale | -6,324 | $14.59 | $92,267 | 2022-05-18 |
| Esposito Pamela | Sale | -3,507 | $14.59 | $51,167 | 2022-05-18 |
| Franchi Jean M. | Sale | -3,436 | $14.59 | $50,131 | 2022-05-18 |
| Patel Sushil | Sale | -10,687 | $14.59 | $155,923 | 2022-05-18 |
| Lewis Tanya | Sale | -5,473 | $14.59 | $79,851 | 2022-05-18 |
| Astley-Sparke Philip | Sale | -9,632 | $14.59 | $140,531 | 2022-05-18 |
| Coffin Robert | Sale | -5,737 | $14.59 | $83,703 | 2022-05-18 |
| Lewis Tanya | Grant, award...etc | 52,500 | 2022-04-05 | ||
| Esposito Pamela | Grant, award...etc | 22,750 | 2022-04-05 | ||
| Love Colin | Grant, award...etc | 26,250 | 2022-04-05 | ||
| Astley-Sparke Philip | Grant, award...etc | 70,000 | 2022-04-05 | ||
| Franchi Jean M. | Grant, award...etc | 52,500 | 2022-04-05 | ||
| Patel Sushil | Grant, award...etc | 52,500 | 2022-04-05 | ||
| Coffin Robert | Grant, award...etc | 26,250 | 2022-04-05 | ||
| Omega Fund IV, L.P. | Sale | -16,500 | $15.42 | $254,430 | 2022-03-16 |
| Omega Fund IV, L.P. | Derivatives Exercise | 16,500 | 2022-03-16 | ||
| Omega Fund IV, L.P. | Sale | -90,000 | $15.64 | $1,407,600 | 2022-03-16 |
| Omega Fund IV, L.P. | Sale | -45,424 | $34.54 | $1,568,945 | 2021-11-23 |
| Omega Fund IV, L.P. | Sale | -5,188 | $33.5 | $173,798 | 2021-11-18 |
| Omega Fund IV, L.P. | Sale | -24,017 | $33.66 | $808,412 | 2021-11-16 |
| Omega Fund IV, L.P. | Sale | -18,290 | $33.5 | $612,715 | 2021-11-12 |
| Omega Fund IV, L.P. | Sale | -11,354 | $33.53 | $380,700 | 2021-11-10 |
| Omega Fund IV, L.P. | Sale | -31,015 | $33.58 | $1,041,484 | 2021-11-08 |
| Love Colin | Sale | -30,000 | $31.16 | $934,800 | 2021-10-19 |
| Omega Fund IV, L.P. | Sale | -12,171 | $33.58 | $408,702 | 2021-09-27 |
| Omega Fund IV, L.P. | Sale | -100,000 | $32.55 | $3,255,000 | 2021-09-20 |
| Love Colin | Sale | -30,000 | $31.23 | $936,900 | 2021-09-17 |
| Love Colin | Sale | -30,000 | $30 | $900,000 | 2021-08-18 |
| Esposito Pamela | Sale | -30,000 | $35 | $1,050,000 | 2021-08-06 |
| Esposito Pamela | Derivatives Exercise | 30,000 | 2021-08-06 | ||
| Esposito Pamela | Sale | -17,400 | $33.05 | $575,070 | 2021-07-22 |
| Esposito Pamela | Derivatives Exercise | 17,400 | 2021-07-22 | ||
| Esposito Pamela | Sale | -59,600 | $45.02 | $2,683,192 | 2021-07-19 |
| Esposito Pamela | Derivatives Exercise | 59,600 | 2021-07-19 | ||
| Love Colin | Sale | -30,000 | $32.02 | $960,600 | 2021-07-16 |
| Coffin Robert | Sale | -7,810 | $40.04 | $312,712 | 2021-07-07 |
| Coffin Robert | Sale | -37,489 | $40.04 | $1,501,060 | 2021-06-30 |
| Love Colin | Sale | -30,000 | $33.8 | $1,014,000 | 2021-06-16 |
| Lewis Tanya | Grant, award...etc | 73,333 | 2021-05-11 | ||
| Patel Sushil | Grant, award...etc | 88,333 | 2021-05-05 | ||
| Love Colin | Sale | -30,000 | $30.69 | $920,700 | 2021-04-19 |
| Astley-Sparke Philip | Grant, award...etc | 85,415 | 2021-04-05 | ||
| Love Colin | Grant, award...etc | 39,285 | 2021-04-05 |
The information provided in this report about REPL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Replimune Group, Inc(NASDAQ:REPL) 
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a...
Website: http://www.replimune.com
Founded: 2015
Full Time Employees: 122
Sector: Healthcare
Industry: Biotechnology